Inhibitory effect of glycyrrhetinic acid derivatives on capsaicin-induced ear edema in mice

Japanese Journal of Pharmacology

Volumn 71, Issue 4, 1996, Pages 281-289

  Inoue, Hideo ^a   Nagata, Nobuyuki ^a   Shibata, Shoji ^a   Koshihara, Yasuko ^b  

^a Minophagen Pharmaceutical Co   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

Capsaicin; Ear edema; Glycyrrhetinic acid derivative; Substance P

Indexed keywords

COMPOUND 48-80; GLYCYRRHETINIC ACID DERIVATIVE; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG STRUCTURE; EAR; EDEMA; EXTRAVASATION; HISTOPATHOLOGY; MALE; MAST CELL; MOUSE; NEUROGENIC INFLAMMATION; NONHUMAN; ORAL DRUG ADMINISTRATION; VASODILATATION;

EID: 0029843959     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.71.281     Document Type: Article

References (33)

1. Finney RSH and Somers GF: The anti-inflammatory activity of glycyrrhetinic acid and derivatives. J Pharm Pharmacol 10, 613-620 (1958)
2. Capasso F, Mascolo N, Autore G and Duraccio MR: Glycyrrhetinic acid, leucocytes and prostaglandins. J Pharm Pharmacol 35, 332-335 (1983)
3. Nishino H, Yoshioka K, Iwashima A, Takizawa H, Konishi S, Okamoto H, Okabe H, Shibata S, Fujiki H and Sugimura T: Glycyrrhetic acid inhibits tumor-promoting activity of teleocidin and 12-O-tetradecanoylphorbol-13-acetate in two-stage mouse skin carcinogenesis. Jpn J Cancer Res 77, 33-38 (1986)
4. Nose M, Ito M, Kamimura K, Shimizu M and Ogihara Y: A comparison of the antihepatotoxic activity between glycyrrhizin and glycyrrhetinic acid. Planta Med 60, 136-139 (1994)
5. Monder C, Stewart PM, Lakshmi V, Valentino R, Burt D and Edwards CRW: Licorice inhibits corticosteroid 11β-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology 125, 1046-1053 (1989)
6. Abe H, Ohya N, Yamamoto KF, Shibuya T, Arichi S and Odashima S: Effects of glycyrrhizin and glycyrrhetinic acid on growth and melanogenesis in cultured B16 melanoma cells. Eur J Cancer Clin Oncol 23, 1549-1555 (1987)
7. Shibata S, Takahashi K, Yano S, Harada M, Saito H, Tamura Y, Kumagai A, Hirabayashi K, Yamamoto M and Nagata N: Chemical modification of glycyrrhetinic acid in relation to the biological activities. Chem Pharm Bull (Tokyo) 35, 1910- 1918 (1987)
8. Kano T, Hashiguchi A, Nakamura M, Morioka T, Mishima M and Nakano M: A comparative study of transdermal 10% lidocaine gel with and without glycyrrhetinic acid monohemiphthalate disodium for pain reduction at venous cannulation. Anesth Analg 74, 535-538 (1992)
9. Inoue H, Saito H, Koshihara Y and Murota S: Inhibitory effect of glycyrrhetinic acid derivatives on lipoxygenase and prostaglandin synthetase. Chem Pharm Bull (Tokyo) 34, 897-901 (1986)
10. Inoue H, Mori T, Shibata S and Koshihara Y: Inhibitory effect of glycyrrhetinic acid derivatives on arachidonic acid-induced mouse ear oedema. J Pharm Pharmacol 40, 272-277 (1988)
11. Inoue H, Kurosu S, Takeuchi T, Mori T and Shibata S: Glycyrrhetinic acid derivatives: anti-nociceptive activity of deoxoglycyrrhetol dihemiphthalate and the related compounds. J Pharm Pharmacol 42, 199-200 (1990)
12. Inoue H, Mori T, Shibata S and Koshihara Y: Modulation by glycyrrhetinic acid derivatives of TPA-induced mouse ear oedema. Br J Pharmacol 96, 204-210 (1989)
13. Inoue H, Inoue K, Takeuchi T, Nagata N and Shibata S: Inhibition of rat acute inflammatory paw oedema by dihemiphthalate of glycyrrhetinic acid derivatives: comparison with glycyrrhetinic acid. J Pharm Pharmacol 45, 1067-1071 (1993)
14. Yano S, Harada M, Watanabe K, Nakamaru K, Hatakeyama Y, Shibata S, Takahashi K, Mori T, Hirabayashi K, Takeda M and Nagata N: Antiulcer activities of glycyrrhetinic acid derivatives in experimental gastric lesion models. Chem Pharm Bull (Tokyo) 37, 2500-2504 (1989)
15. Cristoni A, Nizzola R, Malandrino S and Pifferi G: Synthesis and antiulcer activity of uvaol hemiphthalate derivatives. II Pharmaco 49, 281-284 (1994)
16. Foreman JC: Peptides and neurogenic inflammation. Br Med Bull 43, 386-400 (1987)
17. Holzer P: Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience 24, 739-768 (1988)
18. 1 receptor antagonist blocks capsaicin-induced ear inflammation in mice. Br J Pharmacol 99, 516-518 (1990)
19. Gábor M and Rázga Z: Development and inhibition of mouse ear oedema induced with capsaicin. Agents Actions 36, 83-86 (1992)
20. Inoue H, Nagata N and Koshihara Y: Profile of capsaicin-induced mouse ear oedema as neurogenic inflammatory model: comparison with arachidonic acid-induced ear oedema. Br J Pharmacol 110, 1614-1620 (1993)
21. Inoue H, Nagata N and Koshihara Y: Involvement of substance P as a mediator in capsaicin-induced mouse ear oedema. Inflamm Res 44, 470-474 (1995)
22. Inoue H, Nagata N and Koshihara Y: Participation of serotonin in capsaicin-induced mouse ear edema. Jpn J Pharmacol 69, 61-68 (1995)
23. 1-receptor antagonist, RP 67580, inhibits neurogenic inflammation post-synaptically. Br J Pharmacol 109, 259-264 (1993)
24. Wang J-P, Raung S-L, Lin C-N and Teng C-M: Inhibitory effect of norathyriol, a xanthone from Tripterospermum lanceolatum, on cutaneous plasma extravasation. Eur J Pharmacol 251, 35-42 (1994)
25. Lembeck F and Holzer P: Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol 310, 175-183 (1979)
26. Lembeck F, Donnerer J, Tsuchiya M and Nagahisa A: The non-peptide tachykinin antagonist, CP-96,345, is a potent inhibitor of neurogenic inflammation. Br J Pharmacol 105, 527-530 (1992)
27. Erjavec F, Lembeck F, Florjanc-Irman T, Skofitsch G, Donnerer J, Saria A and Holzer P: Release of histamine by substance P. Naunyn Schmiedebergs Arch Pharmacol 317, 67-70 (1981)
28. Fewtrell CMS, Foreman JC, Jordan CC, Oehme P, Renner H and Stewart JM: The effects of substance P on histamine and 5-hydroxytryptamine release in the rat. J Physiol (Lond) 330, 393-412 (1982)
29. Kiernan JA: Degranulation of mast cells following antidromic stimulation of cutaneous nerves. J Anat 111, 349-350(1971)
30. Leon A, Buriani A, Dal Toso R, Fabris M, Romanello S, Aloe L and Levin-Montalcini R: Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci USA 91, 3739-3743 (1994)
31. Marshall JS and Waserman S: Mast cells and the nerves-potential interactions in the context of chronic disease. Clin Exp Allergy 25, 102-110 (1995)
32. Garret C, Carruette A, Fardin V, Moussaoui S, Peyronel J-F, Blanchard J-C and Laduron PM: Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci USA 88, 10208-10212 (1991)
33. O'Flynn NM, Helme RD, Watkins DJ and Burcher E: Autoradiographic localization of substance P binding sites in rat footpad skin. Neurosci Lett 106, 43-48 (1989)